Lung cancer survival rates are up thanks to immunotherapy, other ... - NPR
WEBApr 12, 2024 · Lung cancer remains the most lethal form of the disease, killing about 135,000 Americans a year – more than breast, prostate and colon cancer combined – which is why many people still think of...
Osimertinib Improves Survival in Lung Cancer - NCI
WEBJul 5, 2023 · A large study of people with early-stage lung cancer and EGFR mutations found that osimertinib, a targeted drug, increased their overall survival after surgery. However, some oncologists questioned the trial design and the benefits of …
Lung cancer treatment produces progression-free survival results …
WEBJun 5, 2024 · A Phase III trial led by Emory University shows that osimertinib, a targeted therapy, reduces the risk of disease progression or death by 84% in patients with stage III non-small cell lung...
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
WEBFeb 16, 2024 · Repotrectinib is a new drug that can shrink tumors in people with advanced lung cancer with ROS1 fusions, a genetic change that makes the cancer cells grow out of control. The drug was approved by FDA in 2023 and can overcome some resistance mutations that other ROS1-targeted drugs cannot.
Lung cancer - Latest research and news - Nature
WEB4 days ago · Latest Research and Reviews. Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.
Targeted Drug Stops Lung Cancer Growth for Five Years in Over …
WEBJun 13, 2024 · A study shows that lorlatinib (Lobrena) stops lung cancer growth and spread for 5 years or more in over half of people with ALK gene mutation. Learn how this drug outperforms crizotinib and how molecular testing can help guide treatment options.
New lung cancer drug an ‘impressive one-two punch’
WEBIn cancer, especially lung cancer, extending survival is really the name of the game. Osimertinib already has an average progression-free survival of 16.6 months, but for the Rybrevant-Lazcluze therapy to extend that to nearly two full years, 23.7 months, is significant for patients.
MSK Researchers Present Advances in Lung Cancer Treatment at …
WEBJun 3, 2024 · MSK scientists reported promising results from clinical trials of combination therapies for KRAS -G12C and EGFR -mutated lung cancers. They also developed a more sensitive liquid biopsy to detect minimal residual disease after surgery.
Pfizer’s Lorbrena extends life for patients with rare lung cancer
WEBMay 31, 2024 · Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a...
US lung cancer survival rates rise, but it’s still the leading ... - CNN
WEBNov 14, 2023 · CNN — Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association. But the...